-- Announcement on Convening the 2025 Semi-annual Performance Briefing
Securities code: 600535 Securities abbreviation: Tasly Number: Lin 2025-055 Tasly Pharmaceutical Group Co., Ltd.
Announcement on Convening the 2025 Semi-annual Results Briefing Meeting
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and bear individual and joint liability for the authenticity, accuracy and completeness of its contents.
Important content reminder:
Meeting time: August 28, 2025 (Thursday) 15:00-16:00 pm
Meeting location: Panoramic Roadshow (https://rs.p5w.net)
Meeting method: online text interaction
Investors can visit the Panorama Investor Relations Interactive Platform (http://ir.p5w.net/zj/) before 16:00 on August 21, 2025 (Thursday) to August 25, 2025 (Monday) to enter the question collection special page, or ask questions through the company’s email [email protected]. The company will answer questions of common concern to investors at the briefing.
Tasly Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") has released the company's 2025 semi-annual report on August 16, 2025. In order to facilitate investors to have a more comprehensive and in-depth understanding of the company's 2025 semi-annual operating results and financial status, the company plans to hold the 2025 2025 Semi-annual Report at 15:00-16:00 on August 28, 2025 in conjunction with the company's controlling shareholder China Resources Sanjiu Pharmaceutical Co., Ltd. and the company's related party Kunyao Group Co., Ltd. Semi-annual results briefing will be held to discuss issues of concern to investors.
1. Type of briefing session
This investor briefing will be held in an interactive online format. The company will interact and communicate with investors on the specific operating results and financial indicators for the first half of 2025, and answer questions of common concern to investors within the scope permitted by information disclosure.
2. Time and place of the briefing meeting
(1) Meeting time: August 28, 2025 (Thursday) 15:00-16:00 pm
(2) Meeting location: Panoramic Roadshow (https://rs.p5w.net)
(3) Meeting method: online text interaction
3. Company participants
Director and General Manager: Mr. Cai Jinyong
Secretary of the Board of Directors: Mr. Yu Jie
Financial Director: Ms. Wei Jie
Independent Director: Ms. Wang Aijian
(Participants may make adjustments if there are special circumstances).
4. How to participate as an investor
(1) Investors can log in to the Panoramic Roadshow (https://rs.p5w.net) from 15:00-16:00 on August 28, 2025 (Thursday) to participate in this briefing online. The company will answer investors’ questions in a timely manner.
(2) Investors can visit the Panorama Investor Relations Interactive Platform (http://ir.p5w.net/zj/) from August 21, 2025 (Thursday) to August 25, 2025 (Monday) before 16:00 to enter the question collection special page, or ask questions through the company's email [email protected]. The company will answer questions of common concern to investors at the briefing.
5. Contact person and consultation method
Contact person: Wang Qi
Tel: 022-26736999, 022-26735302
Email: [email protected]
6. Other matters
After the investor briefing is held, investors can check the status and main content of the investor briefing through Panoramic Roadshow (https://rs.p5w.net).
Announcement is hereby made.
Tasly Pharmaceutical Group Co., Ltd. Board of Directors
August 21, 2025